Bristol Myers Gets European Approval For Opdivo With Chemotherapy To Treat Unresectable Advanced Recurrent Or Metastatic Escc With Tumour Cell Pd L1 Expression 1
Bristol Myers gets European approval for Opdivo with chemotherapy to treat unresectable advanced, recurrent or metastatic ESCC with tumour cell PD-L1 expression 1%
Bristol Myers Squibb announced that the European Commission (EC) has approved Opdivo (nivolumab) in combination with fluoropyrimidine- and platinum-based chemotherapy for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) with tumour cell PD-L1 expression = 1%.
The EC
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!